BARACK-D Trial: Low-Dose Spironolactone and Cardiovascular Outcomes in Moderate Stage Chronic Kidney Disease The BARACK-D trial is a prospective, randomized, open, blinded endpoint study that investigates the effects of low-dose spironolactone in patients with stage 3b chronic kidney disease (CKD) … Read More
spironolactone
The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a complex and increasingly prevalent form of heart failure, accounting for nearly half of all heart failure cases. Despite its significance, HFpEF remains a challenging condition to manage and treat, as effective … Read More